Hong Kong, Hong Kong
Hong Kong, Hong Kong

Time filter

Source Type

News Article | February 15, 2017
Site: www.prweb.com

Career Step, an online provider of career-focused education and professional training, is pleased to announce that it has acquired the Revenue Capture and Coding and Documentation Divisions of Panacea Healthcare Solutions. Career Step and Panacea will now provide end-to-end education, consulting and data analytics solutions to the revenue cycle and healthcare financial marketplaces, further augmenting Career Step’s Professional Training Division. “At Career Step, our focus is on improving lives and business results through education,” said Steve Tober, Career Step President and CEO. “With the acquisition of Panacea and the combination of our complimentary product and service offerings, we will now be able to drive better results for healthcare organizations by tying the information available through their consultants and data analytics to the education we offer. We have been working closely with Panacea for the past two years, and we have proven through our joint efforts that our combined offerings can meet an important market need.” Founded in 2007 and based in St. Paul, Minnesota, with additional offices in New Jersey and Florida, Panacea Healthcare Solutions provides expert coding, compliance, technology and financial advice to hundreds of healthcare providers each year. These services help healthcare organizations improve their bottom line, and industry-proven Panacea products and strategies include CLAIMSauditor®, I10Focus™ and Hospital Zero-Base Pricing®. “The Panacea team is excited to join Career Step,” said Frederick Stodolak, Panacea CEO at the time of the acquisition. “Both companies have worked successfully together for years, and we look forward to integrating our combined talent and technology to offer our clients a more synergistic and comprehensive offering. The combined business model is unique in that we provide learning solutions at the onset of individuals’ careers as well as integrated educational, consulting and technology services to support them throughout their career lifetime.” Career Step’s acquisition focuses on tying its educational offerings to the information available through consulting and data analytics. This acquisition also brings more than 25 industry experts in-house, which will augment Career Step’s Professional Training division and enable faster development and delivery of educational products. “Since the implementation of ICD-10, the need for new and continuing revenue cycle education has grown,” said Mike Hodgson, Career Step Professional Training Division Executive Vice President. “The combination of Career Step’s programs and Panacea’s consulting services and data analytics software will enable us to identify opportunities for revenue improvement by capturing lost charges and underbilled services and then improving pricing models based on actual costs. The information we gather for clients through consulting and software services will help us identify areas for education that will facilitate long-term staff performance improvement.” Career Step will run the Panacea Healthcare Solution business as an independent brand and entity within the Career Step Professional Training Division, and as part of the transaction Frederick Stodolak and others on the current Panacea management team will continue as shareholders. The transaction closed February 1, 2017, and Hogan Lovells US LLP acted as exclusive legal advisor to Career Step. More information on the available products can be found at http://www.panaceainc.com. About Career Step Career Step, a portfolio company of Denver-based equity firm Revelstoke Capital partners, is an online provider of career-focused education and professional training. The company has trained over 100,000 students for new careers, has more than 150 partnerships with colleges and universities nationwide, offers a variety of continuing education courses for healthcare professionals and has educated more than 8,000 health information professionals through its Professional Training Division. Career Step provides training for several of the largest and most respected healthcare employers in the nation and is committed to helping students and practicing healthcare professionals alike gain the skills they need to be successful in the workplace—improving lives, advancing careers and bettering business results through education. More information can be found at http://www.careerstep.com or 1-800-246-7836. About Panacea Healthcare Solutions Panacea Healthcare Solutions, a Career Step company, provides expert coding, compliance, financial consulting and information technology to hundreds of healthcare providers and organizations each year to proactively maintain compliance and identify risk and new incremental net revenue opportunities. Each solution is rooted in Panacea’s extensive frontline experience in healthcare finance and coding, including chargemaster and coding compliance auditing, CLAIMSauditor®, I10Focus™ and Hospital Zero-Base Pricing®, which has earned the coveted HFMA Peer Review® designation. The company maintains offices in Minnesota, New Jersey and Florida. More information can be found at http://www.panaceainc.com or 1-800-252-1578.


News Article | October 28, 2016
Site: www.prweb.com

Career Step, an online provider of career-focused education and professional training, is pleased to announce its acquisition of Medic-CE, LLC, one of the leading providers of online continuing education for emergency medical service (EMS) and firefighting professionals. This acquisition expands Career Step’s professional training offerings into another sector of healthcare. “At Career Step, we continue to focus on helping people improve their lives and advance their careers through education designed for real application in the healthcare arena,” said Steve Tober, Career Step President and CEO. “The acquisition of Medic-CE enables us to take our education and innovative training one step further. We are now able to combine Medic-CE’s robust learning and record management system and its considerable online continuing education course library, with our live online, instructor-led training, which we added this past January through the acquisition of Code3 CME. This combination of tools is the only unified solution in the market that enables EMS professionals to meet all of their didactic continuing education requirements in one place.” Founded in 2006 and based in Houston, Texas, Medic-CE currently serves more than 75,000 individual learners and 200 EMS and fire agencies. The company offers self-paced online continuing education that is written and developed by subject matter experts. All of the EMS programs are nationally accredited by the Commission on Accreditation for Pre-Hospital Continuing Education (CAPCE) and are accepted by the National Registry of Emergency Medical Technicians (NREMT). “With high-quality courses and easy-to-use technology, Medic-CE has grown to become one of the largest providers of EMS online continuing education over the past eight years,” said Richard Ezzeddine, MD, co-founder of Medic-CE. “Teaming up with Career Step provides a unique opportunity to rapidly expand our course offerings and further enhance our technology as well as become the first company to offer virtual instructor-led training through an advanced learning management platform. Our ultimate goal is to increase customer satisfaction and ensure we continue to be a pioneer in the online EMS continuing education space.” Career Step’s acquisition focuses on improving the experiences of its learners within the EMS field. The online format aligns with Career Step’s portfolio of education products, and the acquisition simplifies continuing education by providing the opportunity to meet all didactic training requirements through one vendor. “As an emergency medical services and fire educator with nearly 20 years of experience, I understand first-hand the challenges departments face delivering healthcare education to their staff,” said Judson Smith, Career Step Vice President of Continuing Education. “This is why I am so excited for the time savings and convenience that will be provided for these agencies with the 24/7 access to online instructor-led training as well as self-paced curriculum within one platform. In the business of saving life and property, this is extremely valuable to our fire and EMS professionals.” Career Step will run the Medic-CE business as an independent brand and entity within Career Step’s Professional Training Division. The transaction closed September 30, 2016, and Hogan Lovells US LLP acted as exclusive legal advisor to Career Step. More information on the available products can be found at Medic-CE.com. About Career Step Career Step, a portfolio company of Denver-based equity firm Revelstoke Capital partners, is an online provider of career-focused education and professional training. The company has trained over 100,000 students for new careers, has more than 150 partnerships with colleges and universities nationwide, offers a variety of continuing education courses for healthcare professionals and has educated more than 8,000 health information professionals through its Professional Training Division. Career Step provides training for several of the largest and most respected healthcare employers in the nation and is committed to helping students and practicing healthcare professionals alike gain the skills they need to be successful in the workplace—improving lives, advancing careers and bettering business results through education. More information can be found at http://www.careerstep.com or 1-800-246-7836. About Medic-CE Medic-CE, a Career Step company, provides accredited online continuing education for EMS and firefighting professionals. Founded in 2006, the company currently serves over 75,000 learners and 200 fire/EMS departments. More than 200 hours of continuing education are available through the company’s powerful learning management system. The company also offers the Code3 CME Virtual Instructor-Led Training (VILT) Solution and the option for departments to add their own in-house continuing education and instructor-led courses to its sophisticated yet simple learning platform. More information is available at Medic-CE.com or 1-877-458-9498.


News Article | December 16, 2016
Site: www.PR.com

Marketforce to Host Insurance Fraud on 6th March 2017 in London If you’re dedicated to defending your customers and your industry from fraudsters, and you want to share ideas with more than 130 of your peers, Insurance Fraud is the conference you need to attend in 2017. London, United Kingdom, December 16, 2016 --( Highlights for 2017? · David Hertzell, Chair of the Insurance Fraud Taskforce, provides a critical update on the industry reform agenda · Gain a board-level perspective on the evolving threat landscape with Amanda Blanc, Group CEO of AXA and Chair of the Insurance Fraud Bureau · Explore the latest innovations in the fight against fraud, from Internet of Things and telematics, to blockchain and machine learning · The IFB and MIB reveal more details about the forthcoming Insurance Intelligence Hub Last year’s conference included delegates from: Ageas, Allianz Group, Association of British Insurers, Aviva, BAE Systems, Chaucer Insurance, Clyde & Co, comparethemarket.com, Confused.com, Covéa Insurance, Direct Line Group, Equifax, Esure Insurance, Experian, Hastings Insurance Group, Gocompare.com, Insurance Fraud Bureau, Hogan Lovells, LexisNexis, LV=, RSA Security, Swinton Group, The A&A Group, The Co-operative Insurance, Ultimate Insurance Solutions, Zurich Insurance Group. Please visit the website at http://bit.ly/2gALHhH for more information on the programme and speakers. For any queries call +44 (0)207 760 8699 or send an email at conferences@marketforce.eu.com. London, United Kingdom, December 16, 2016 --( PR.com )-- As fraud becomes ever more sophisticated and costly this dedicated one-day conference will explore a holistic approach to fraud, examining initiatives for industry wide reform, as well as how anti-fraud measures and technology can become part of a company-wide strategy, from underwriting to application, claims and prosecution.Highlights for 2017?· David Hertzell, Chair of the Insurance Fraud Taskforce, provides a critical update on the industry reform agenda· Gain a board-level perspective on the evolving threat landscape with Amanda Blanc, Group CEO of AXA and Chair of the Insurance Fraud Bureau· Explore the latest innovations in the fight against fraud, from Internet of Things and telematics, to blockchain and machine learning· The IFB and MIB reveal more details about the forthcoming Insurance Intelligence HubLast year’s conference included delegates from:Ageas, Allianz Group, Association of British Insurers, Aviva, BAE Systems, Chaucer Insurance, Clyde & Co, comparethemarket.com, Confused.com, Covéa Insurance, Direct Line Group, Equifax, Esure Insurance, Experian, Hastings Insurance Group, Gocompare.com, Insurance Fraud Bureau, Hogan Lovells, LexisNexis, LV=, RSA Security, Swinton Group, The A&A Group, The Co-operative Insurance, Ultimate Insurance Solutions, Zurich Insurance Group.Please visit the website at http://bit.ly/2gALHhH for more information on the programme and speakers. For any queries call +44 (0)207 760 8699 or send an email at conferences@marketforce.eu.com.


News Article | February 15, 2017
Site: www.prweb.com

Global law firm Greenberg Traurig, LLP further grew its Corporate Practice with two strategic additions, Joseph Suh and Ejim Peter Achi as shareholders in New York. They join Greenberg Traurig as the firm continues to enhance its Corporate Practice, specifically in the areas of mergers and acquisitions, private equity and investment management. In 2016, nearly 90 attorneys joined the firm’s Corporate Practice, with more than 20 in New York. “As the marketplace changes and becomes increasingly complex and global, Greenberg Traurig is focused on attracting premier specialists, like Joseph and Ejim, to support those changes. On a variety of levels, we offer a tremendous value proposition in the M&A, private equity and investment management arenas,” said Richard A. Rosenbaum, Greenberg Traurig Executive Chairman. Suh focuses on corporate and securities matters related to investment funds and financial products, and has substantial experience in representing investment managers and investors in connection with formation of and investments in collateralized loan obligations (CLOs), hedge funds and private equity funds, including private funds investing in asset-backed securities, distressed assets, marketplace loans and Brazilian assets. Achi represents private equity sponsors, public and private strategic buyers and sellers, and venture capital investors in connection with buyouts, mergers, acquisitions, divestitures, joint ventures and other investments. “The CLO market is underserved today and Joseph is one of the few attorneys in the United States who has his level of experience. Both he and Ejim have unique, real-world experience in foreign markets, making them a great fit within our award-winning global platform. We are excited to add them to our already talented roster,” said Patricia Menéndez-Cambó, Global Vice Chair of Greenberg Traurig. Per Nancy Mitchell and Stephen Rabinowitz, Co-Managing Shareholders of Greenberg Traurig’s New York office, “We welcome Ejim and Joseph to our robust New York practice as two of our three new additions since the start of 2017. Greenberg Traurig is a firm built for today's client needs that added more than 70 attorneys and directors throughout New York State and the Metropolitan Region in 2016.” Also on Jan. 17, former Deputy Secretary of Legislative Affairs for New York State Governor Andrew Cuomo, Mark Weprin joined the firm in its New York City and Albany offices and Rebecca L. Caldwell-Harrigal, the first female Director of the Office of Tax Exempt Bonds (TEB) at the Internal Revenue Service (IRS), joined as a shareholder in the Tax Practice in our Northern Virginia office. Additionally, on Jan. 18, six new shareholders and related teams focused on private equity, real estate and tax joined the firm’s London office. “Greenberg Traurig is an excellent fit for my clients and for my experience based on the firm’s goals and strategy. It is particularly important that I am joining at this time, given the firm’s focus in growing its investment management practice and, especially in my case, CLOs, hedge funds, private equity funds and related financial vehicles,” Suh said. “I have worked with Greenberg Traurig attorneys previously and it’s great to be part of the team.” “This is a tremendous opportunity to grow my practice while serving as an asset to Greenberg Traurig’s clients on a global scale. The firm’s highly respected reputation for prudent management and excellence in the delivery of quality legal services are key factors in my decision to join at this time,” Achi said. Suh, who speaks Portuguese and Korean, lived in Brazil for nine years and has significant experience with the Brazilian investment management industry. He advises them in structuring the investment funds and in connection with all related U.S. corporate, securities and investment adviser regulatory issues. He received his J.D. in 1994 from Fordham University School of Law and his B.A. in Government from Cornell University in 1991. Prior to joining Greenberg Traurig, he was a partner at Schulte Roth & Zabel LLP, where he coordinated that firm's Latin America practice. Achi represents clients in joint ventures, acquisitions and venture capital transactions involving a number of jurisdictions, including a number of African targets. In 2011, he received the Accelerator Award from the MIT Sloan School of Business Africa Innovate Business Plan Competition. He earned his J.D. in 2006 from the University of Pennsylvania Law School, where he also received a Certificate in Business & Public Policy from The Wharton School of Business. In 2002, he received his B.A. from the University of Pennsylvania. Achi also received an MBA from the Yale School of Management in 2013. Prior to joining Greenberg Traurig, he practiced at Hogan Lovells. Greenberg Traurig’s Private Equity Practice utilizes the collective experience and resources of the firm to help clients achieve their goals. An experienced team of private equity attorneys leverages the firm’s unique geographic platform and extensive range of practice and industry capabilities across the firm, which distinguishes Greenberg Traurig from other large firms. To learn more about Greenberg Traurig’s Private Equity Practice, click here. Greenberg Traurig’s Corporate & Securities Practice comprises more than 400 lawyers who advise public and privately held companies and investment funds on global mergers and acquisitions, corporate restructurings, private equity and venture capital, underwritten and syndicated offerings, commercial finance and syndicated lending, cross-border transactions, and general corporate matters. The group’s industry experience includes transactions in a wide range of fields, from the pharmaceutical, medical devices, and life sciences fields, to representations involving clients in the aviation, banking, energy, health care, manufacturing, technology, and telecommunications sectors. Greenberg Traurig, LLP (GTLaw) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East and is celebrating its 50th anniversary. A single entity worldwide, GTLaw has been recognized for its philanthropic giving, was named the second largest firm in the U.S. by Law360 in 2016, and among the Top 20 on the 2016 Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law.


Basal cell carcinoma and squamous cell carcinoma (skin cancers) selected, representing over 5,500,000 diagnoses annually in the US alone, making it the most prevalent cancer today KENNEWICK, WA / ACCESSWIRE / February 28, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released the third letter in a four letter series outlining AMI's push towards FDA submittal and commercialization from its new President & CEO, Dr. Mike Korenko. After two months of dynamic experience-based discussions among our Medical Advisory Board Members and other senior doctors we have selected our first indication for use which we will present to the Food and Drug Administration. After thorough review to prioritize indications, we have selected basal cell and squamous cell carcinoma (skin cancers). The reasons for this important selection relates to our criteria below: This cancer is in the skin and therefore easy to access. Single injections for small tumors are easy and we have already demonstrated our parallel injection procedure in the cat at Washington State University for larger tumors. b. Therapeutic ratio (ratio of the dose to the tumor target tissue relative to dose to adjacent normal tissue) and responsiveness to radiation: Yttrium-90 is a beta emitter in RadioGel has a much higher therapeutic ratio than any gamma emitter or external beam therapy. Since Y-90 delivers high-energy beta-rays, it has an average penetration path of 4 to 5 mm (less than a quarter inch), which is ideal for skin cancer therapy. There is minimal irradiation of normal surrounding tissue. As an added bonus, the patient can go home immediately with no irradiation risk to themselves or family members. We can treat with very high doses, so response to radiation would not be an issue. (As a comparison, external beam radiation can deliver 60 to 80 Gy. Yttrium-90 in RadioGel can go to 700 Gy or higher). As discussed above, there is very low risk of collateral damage. In addition, the skin is not located next to a major organ, for example if you were injecting near spinal tumors. Because of the low collateral risk and because of the therapeutic effects that would be relatively easy to see in three months, the Medical Advisory Board felt this might be an easier device for the FDA to approve and in a shorter timeframe. In addition, some of our animal testing, that will start in about two months, are already treating similar cancers. We intentionally avoided applying to the FDA for melanoma, since it is highly metastatic and goes deep into the tissue. There are a much smaller number of cases for this cancer type (around 300,000). In addition, there are three new immunotherapy products on the market to treat melanoma cancer. They can have serious side-effects, but they are promising. That violates our next criterion below. Some skin cancers require several-hour long surgeries in which the tumor is removed, one layer at a time, and then sent for biopsy. They then require a skin graft that can lead to an infection. On tumors of the face this can be disfiguring. As people get older their skin gets thinner, which increases the difficulty. Our Advisory Board felt that for these cases in particular RadioGel has a significant therapeutic advantage. It would benefit the patient and contribute to reducing the cost of health care. 3. CAN BE PROFITABLY EMBRACED BY THE MEDICAL COMMUNITY: One out of every three new cancers in the United States is a cancerous skin lesion. The two skin cancer types that we selected are the most common. There are 3.3 million patients in the United States with 5.5 million tumors (some patients have more than one tumor.) About 1 million of these are squamous cell cancers located near the surface of the epidermal skin layer, and greater than 4 million are basal cell cancers in the deep layer of the epidermis. I would never say that we can treat them all; that would just be marketing hype, but I believe that this will be the preferred treatment in a substantial number of cases in a very large market. b. Ease of acceptance by the medical community, Medicare reimbursement: The potential lower cost of RadioGel therapy coupled with the potential very large number of patients satisfied this criterion. To further test the criterion, we are in discussions with a major private clinic with several skin treatment centers. This client believes this is a great new tool for their toolbox. They are also advising us on the obstacles that will have to be overcome, such as our Medicare reimbursement criterion. Since we believe RadioGel therapy will reduce the cost to Medicare we are confident that will not be an obstacle. There are other cancer types on our list of eighteen potential indications of use for RadioGel, and we have already prioritized to present them to the FDA in the future. Unfortunately, in the meantime, those patients will not be benefiting from this technology. As I have reported in my last shareholder letter, I am aligning the veterinarian animal testing with the human skin cancer. Specially, the University of Missouri will be focusing on the treatment for surface soft cell lesions, and Colorado State University will be refining the therapies for oral squamous cell cancers. After this selection, our next step is to prepare for the FDA pre-submittal meeting. We will request that meeting after we complete the test plans that will answer their previous questions. Until we complete these plans I can only estimate that our pre-submission to the FDA would be in June. I am really happy that we have engaged John Smith from Hogan Lovells to be at our side through this FDA process. I am excited and relieved that this selection decision had been made and I wanted to thank the members of our Medical Advisory Board – Chairman Dr. Barry D. Pressman, Dr. Albert DeNittis, Dr. Howard Sandler, and Dr. Darrell Fisher. I would also like to thank Dr. Ricardo Paz-Fumagalli and Dr. Beau Bosko Toskich from the Mayo Clinic for their valuable advice. In addition to the important developments discussed above, we continue to believe that the public markets are significantly undervaluing our company. With a fully diluted enterprise value of less than $10 million, there remains very large upside potential. As we progress on our plan, I intend to work vigorously to educate and inform the medical and investment community as to the therapeutic benefits our core technology as well as the economic model that can generate significant revenue and profits. We are committed to pursuing an uplisting to a national exchange as soon as possible in order to gain wider exposure and credibility in our pursuit of the multi-billion-dollar addressable market for Radiogel™, that can both significantly improve patient outcomes and reward shareholders. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


Basal cell carcinoma and squamous cell carcinoma (skin cancers) selected, representing over 5,500,000 diagnoses annually in the US alone, making it the most prevalent cancer today KENNEWICK, WA / ACCESSWIRE / February 28, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released the third letter in a four letter series outlining AMI's push towards FDA submittal and commercialization from its new President & CEO, Dr. Mike Korenko. After two months of dynamic experience-based discussions among our Medical Advisory Board Members and other senior doctors we have selected our first indication for use which we will present to the Food and Drug Administration. After thorough review to prioritize indications, we have selected basal cell and squamous cell carcinoma (skin cancers). The reasons for this important selection relates to our criteria below: This cancer is in the skin and therefore easy to access. Single injections for small tumors are easy and we have already demonstrated our parallel injection procedure in the cat at Washington State University for larger tumors. b. Therapeutic ratio (ratio of the dose to the tumor target tissue relative to dose to adjacent normal tissue) and responsiveness to radiation: Yttrium-90 is a beta emitter in RadioGel has a much higher therapeutic ratio than any gamma emitter or external beam therapy. Since Y-90 delivers high-energy beta-rays, it has an average penetration path of 4 to 5 mm (less than a quarter inch), which is ideal for skin cancer therapy. There is minimal irradiation of normal surrounding tissue. As an added bonus, the patent can go home immediately with no irradiation risk to themselves or family members. We can treat with very high doses, so response to radiation would not be an issue. (As a comparison, external beam radiation can deliver 60 to 80 Gy. Yttrium-90 in RadioGel can go to 700 Gy or higher). As discussed above, there is very low risk of collateral damage. In addition, the skin is not located next to a major organ, for example if you were injecting near spinal tumors. Because of the low collateral risk and because of the therapeutic effects that would be relatively easy to see in three months, the Medical Advisory Board felt this might be an easier device for the FDA to approve and in a shorter timeframe. In addition, some of our animal testing, that will start in about two months, are already treating similar cancers. We intentionally avoided applying to the FDA for melanoma, since it is highly metastatic and goes deep into the tissue. There are a much smaller number of cases for this cancer type (around 300,000). In addition, there are three new immunotherapy products on the market to treat melanoma cancer. They can have serious side-effects, but they are promising. That violates our next criterion below. Some skin cancers require several-hour long surgeries in which the tumor is removed, one layer at a time, and then sent for biopsy. They then require a skin graft that can lead to an infection. On tumors of the face this can be disfiguring. As people get older their skin gets thinner, which increases the difficulty. Our Advisory Board felt that for these cases in particular RadioGel has a significant therapeutic advantage. It would be comparatively benefit the patient and contribute to reducing the cost of health care. 3. CAN BE PROFITABLY EMBRACED BY THE MEDICAL COMMUNITY: One out or every three new cancers in the United States is a cancerous skin lesion. The two skin cancer types that we selected are the most common. There are 3.3 million patients in the United States with 5.5 million tumors (some patients have more than one tumor.) About 1 million of these are squamous cell cancers located near the surface of the epidermal skin layer, and greater than 4 million are basal cell cancers in the deep layer of the epidermis. I would never say that we can treat them all; that would just be marketing hype, but I believe that this will be the preferred treatment in a substantial number of cases in a very large market. b. Ease of acceptance by the medical community, Medicare reimbursement: The potential lower cost of RadioGel therapy coupled with the potential very large number of patients satisfied this criterion. To further test the criterion, we are in discussions with a major private clinic with several skin treatment centers. This client believes this is a great new tool for their toolbox. They are also advising us on the obstacles that will have to be overcome, such our Medicare reimbursement criterion. Since we believe RadioGel therapy will reduce the cost to Medicare we are confident that will not be an obstacle. There are other cancer types on our list of eighteen potential indications of use for RadioGel, and we have already prioritized to present them to the FDA in the future. Unfortunately, in the meantime, those patients will not be befitting from this technology. As I have reported in my last shareholder letter, I am aligning the veterinarian animal testing with the human skin cancer. Specially, the University of Missouri will be focusing on the treatment for surface soft cell lesions, and Colorado State University will be refining the therapies for oral squamous cell cancers. After this selection, our next step is to prepare for the FDA pre-submittal meeting. We will request that meeting after we complete the test plans that will answer their previous questions. Until we complete these plans I can only estimate that our pre-submission to the FDA would be in June. I am really happy that we have engaged John Smith from Hogan Lovells to be at our side through this FDA process. I am excited and relieved that this selection decision had been made and I wanted to thank the members of our Medical Advisory Board – Chairman Dr. Barry D. Pressman, Dr. Albert DeNittis, Dr. Howard Sandler, and Dr. Darrell Fisher. I would also like to thank Dr. Ricardo Paz-Fumagalli and Dr. Beau Bosko Toskich from the Mayo Clinic for their valuable advice. In addition to the important developments discussed above, we continue to believe that the public markets are significantly undervaluing our company. With a fully diluted enterprise value of less than $10 million, there remains very large upside potential. As we progress on our plan, I intend to work vigorously to educate and inform the medical and investment community as to the therapeutic benefits our core technology as well as the economic model that can generate significant revenue and profits. We are committed to pursuing an uplisting to a national exchange as soon as possible in order to gain wider exposure and credibility in our pursuit of the multi-billion-dollar addressable market for Radiogel™, that can both significantly improve patient outcomes and reward shareholders. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control. Basal cell carcinoma and squamous cell carcinoma (skin cancers) selected, representing over 5,500,000 diagnoses annually in the US alone, making it the most prevalent cancer today KENNEWICK, WA / ACCESSWIRE / February 28, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released the third letter in a four letter series outlining AMI's push towards FDA submittal and commercialization from its new President & CEO, Dr. Mike Korenko. After two months of dynamic experience-based discussions among our Medical Advisory Board Members and other senior doctors we have selected our first indication for use which we will present to the Food and Drug Administration. After thorough review to prioritize indications, we have selected basal cell and squamous cell carcinoma (skin cancers). The reasons for this important selection relates to our criteria below: This cancer is in the skin and therefore easy to access. Single injections for small tumors are easy and we have already demonstrated our parallel injection procedure in the cat at Washington State University for larger tumors. b. Therapeutic ratio (ratio of the dose to the tumor target tissue relative to dose to adjacent normal tissue) and responsiveness to radiation: Yttrium-90 is a beta emitter in RadioGel has a much higher therapeutic ratio than any gamma emitter or external beam therapy. Since Y-90 delivers high-energy beta-rays, it has an average penetration path of 4 to 5 mm (less than a quarter inch), which is ideal for skin cancer therapy. There is minimal irradiation of normal surrounding tissue. As an added bonus, the patent can go home immediately with no irradiation risk to themselves or family members. We can treat with very high doses, so response to radiation would not be an issue. (As a comparison, external beam radiation can deliver 60 to 80 Gy. Yttrium-90 in RadioGel can go to 700 Gy or higher). As discussed above, there is very low risk of collateral damage. In addition, the skin is not located next to a major organ, for example if you were injecting near spinal tumors. Because of the low collateral risk and because of the therapeutic effects that would be relatively easy to see in three months, the Medical Advisory Board felt this might be an easier device for the FDA to approve and in a shorter timeframe. In addition, some of our animal testing, that will start in about two months, are already treating similar cancers. We intentionally avoided applying to the FDA for melanoma, since it is highly metastatic and goes deep into the tissue. There are a much smaller number of cases for this cancer type (around 300,000). In addition, there are three new immunotherapy products on the market to treat melanoma cancer. They can have serious side-effects, but they are promising. That violates our next criterion below. Some skin cancers require several-hour long surgeries in which the tumor is removed, one layer at a time, and then sent for biopsy. They then require a skin graft that can lead to an infection. On tumors of the face this can be disfiguring. As people get older their skin gets thinner, which increases the difficulty. Our Advisory Board felt that for these cases in particular RadioGel has a significant therapeutic advantage. It would be comparatively benefit the patient and contribute to reducing the cost of health care. 3. CAN BE PROFITABLY EMBRACED BY THE MEDICAL COMMUNITY: One out or every three new cancers in the United States is a cancerous skin lesion. The two skin cancer types that we selected are the most common. There are 3.3 million patients in the United States with 5.5 million tumors (some patients have more than one tumor.) About 1 million of these are squamous cell cancers located near the surface of the epidermal skin layer, and greater than 4 million are basal cell cancers in the deep layer of the epidermis. I would never say that we can treat them all; that would just be marketing hype, but I believe that this will be the preferred treatment in a substantial number of cases in a very large market. b. Ease of acceptance by the medical community, Medicare reimbursement: The potential lower cost of RadioGel therapy coupled with the potential very large number of patients satisfied this criterion. To further test the criterion, we are in discussions with a major private clinic with several skin treatment centers. This client believes this is a great new tool for their toolbox. They are also advising us on the obstacles that will have to be overcome, such our Medicare reimbursement criterion. Since we believe RadioGel therapy will reduce the cost to Medicare we are confident that will not be an obstacle. There are other cancer types on our list of eighteen potential indications of use for RadioGel, and we have already prioritized to present them to the FDA in the future. Unfortunately, in the meantime, those patients will not be befitting from this technology. As I have reported in my last shareholder letter, I am aligning the veterinarian animal testing with the human skin cancer. Specially, the University of Missouri will be focusing on the treatment for surface soft cell lesions, and Colorado State University will be refining the therapies for oral squamous cell cancers. After this selection, our next step is to prepare for the FDA pre-submittal meeting. We will request that meeting after we complete the test plans that will answer their previous questions. Until we complete these plans I can only estimate that our pre-submission to the FDA would be in June. I am really happy that we have engaged John Smith from Hogan Lovells to be at our side through this FDA process. I am excited and relieved that this selection decision had been made and I wanted to thank the members of our Medical Advisory Board – Chairman Dr. Barry D. Pressman, Dr. Albert DeNittis, Dr. Howard Sandler, and Dr. Darrell Fisher. I would also like to thank Dr. Ricardo Paz-Fumagalli and Dr. Beau Bosko Toskich from the Mayo Clinic for their valuable advice. In addition to the important developments discussed above, we continue to believe that the public markets are significantly undervaluing our company. With a fully diluted enterprise value of less than $10 million, there remains very large upside potential. As we progress on our plan, I intend to work vigorously to educate and inform the medical and investment community as to the therapeutic benefits our core technology as well as the economic model that can generate significant revenue and profits. We are committed to pursuing an uplisting to a national exchange as soon as possible in order to gain wider exposure and credibility in our pursuit of the multi-billion-dollar addressable market for Radiogel™, that can both significantly improve patient outcomes and reward shareholders. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


Hires Expert FDA Device Submission Firm; Outlines In-Parallel FDA Data Collection Strategy; Expands Medical Advisory Board with Doctors from 2 Top Cancer Hospitals; Narrows Indication List from 18 to 6 KENNEWICK, WA / ACCESSWIRE / February 14, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released a letter from its new President and CEO, Dr. Mike Korenko: With my first letter on January 11, I shared AMI's plans for our near-term future. With this letter, I will discuss the progress on that plan in the medical sector of our business over the last month. PATH FORWARD WITH THE FOOD AND DRUG ADMINISTRATION (FDA) In order to maximize our expertise in communicating with the FDA, I spent a lot of time locating the correct FDA expert to be at our side. We have engaged Hogan Lovells. They have 21 lawyers in the field of FDA devices and are very familiar with the personnel at the FDA. We are thrilled to have the input of senior partner John Smith, M.D., J.D. As both a physician and a lawyer, John combines clinical and regulatory experience relating to the FDA with a practical approach to addressing the regulatory issues. He places a particular focus on bringing device-based technologies to market. John and his lawyers have just completed the review of all our previous FDA communications and our supporting data. Based on their recommendations with respect to interacting with the FDA, we intend to: 1. Introduce AMI's new leadership and let them know we have listened; we are narrowing our indication for use to secure our first approval and completing the test plans to answer their previous questions for their review. 2. Present our specific test plans and data in a Pre-Submission meeting to clarify the final application. 4. With the FDA's permission, submit a de novo application for approval (FDA.gov De Novo Application FAQs). The FDA classification of RadioGel™ as a device increases our chances of a timely FDA approval exponentially. The critical path on the overall schedule to approval is, first, to complete laboratory testing concurrent with veterinary animal studies, then into human clinical trials. It is my intent to align the animal treatments in our veterinarian business division to support the animal testing required for the FDA to synergize the two divisions, and potentially create time and cost savings. In this parallel strategy, the company looks to move to first-in-man trials as soon as possible, while aggressively pursuing near-term revenues through the veterinary division, IsoPet, and through licensing. Our Medical Advisory Board has been expanded. Under the Chairmanship of Dr. Barry Pressman (a neuroradiology expert at Cedars-Sinai Medical Center in Los Angeles and Past-President of the American College of Radiology), the Board now includes Dr. Albert Denittis (Chief of Radiation Oncology Lankenau Medical Center), and Dr. Howard Sandlin (Ronald H. Bloom Chair in Cancer Therapeutics, Professor and Chair, Department of Radiation Oncology, Cedars-Sinai Medical Center). Their combined medical experience adds up to over 125 years. We have also been harvesting advice from other doctors, including two from the Mayo Clinic. The focus of the Advisory Boards is to prioritize our indications for use (which cancer types to treat first) in order to present them one at a time, in sequence to the FDA. The Board has selected 18 cancers that are good candidates for treatment with RadioGel™. To me, this large number is a confirmation of our belief that RadioGel has broad potential to treat a variety of tumors. From a business standpoint, it set the stage for incremental growth for many years into the future. In the near-term, we are prioritizing this list down to our top three therapy targets based on specific criteria. 1. Potential for FDA approval and successful therapy: a. Accessibility in the body, ease of application b. Therapeutic effectiveness in response to radiation c. Potential collateral risks from injection d. FDA Testing requirements 3. Business considerations a. Number of patients diagnosed yearly b. Ease of acceptance by the medical community c. Medical Insurance and Medicare reimbursement To paraphrase: 1) It works; 2) Nobody has a better mousetrap; and 3) It has to be profitable to the medical business sector. There have been other great products that made it through the FDA and failed, since the medical community did not see a profitable way to adapt the new technology. The medical community cares about saving lives, but they are in a business. We did not want to be surprised by that reality. As of today, we are down to six near-term candidates. We hope to have our final selection before the end of February. This is an important decision, so we need to get it right. I will send out another shareholder letter when we select our first indication for use. I will also discuss our veterinarian sector's business plan, as well as some updates in a near-term communication to you. I hope this was not too much detail, but I am not a big fan of fluff. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners, and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control. Hires Expert FDA Device Submission Firm; Outlines In-Parallel FDA Data Collection Strategy; Expands Medical Advisory Board with Doctors from 2 Top Cancer Hospitals; Narrows Indication List from 18 to 6 KENNEWICK, WA / ACCESSWIRE / February 14, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a cancer therapeutics company focused on the commercialization of their RadioGel™ device, a tumor-injectable and biodegradable radiation that remains focused at the treatment site, today released a letter from its new President and CEO, Dr. Mike Korenko: With my first letter on January 11, I shared AMI's plans for our near-term future. With this letter, I will discuss the progress on that plan in the medical sector of our business over the last month. PATH FORWARD WITH THE FOOD AND DRUG ADMINISTRATION (FDA) In order to maximize our expertise in communicating with the FDA, I spent a lot of time locating the correct FDA expert to be at our side. We have engaged Hogan Lovells. They have 21 lawyers in the field of FDA devices and are very familiar with the personnel at the FDA. We are thrilled to have the input of senior partner John Smith, M.D., J.D. As both a physician and a lawyer, John combines clinical and regulatory experience relating to the FDA with a practical approach to addressing the regulatory issues. He places a particular focus on bringing device-based technologies to market. John and his lawyers have just completed the review of all our previous FDA communications and our supporting data. Based on their recommendations with respect to interacting with the FDA, we intend to: 1. Introduce AMI's new leadership and let them know we have listened; we are narrowing our indication for use to secure our first approval and completing the test plans to answer their previous questions for their review. 2. Present our specific test plans and data in a Pre-Submission meeting to clarify the final application. 4. With the FDA's permission, submit a de novo application for approval (FDA.gov De Novo Application FAQs). The FDA classification of RadioGel™ as a device increases our chances of a timely FDA approval exponentially. The critical path on the overall schedule to approval is, first, to complete laboratory testing concurrent with veterinary animal studies, then into human clinical trials. It is my intent to align the animal treatments in our veterinarian business division to support the animal testing required for the FDA to synergize the two divisions, and potentially create time and cost savings. In this parallel strategy, the company looks to move to first-in-man trials as soon as possible, while aggressively pursuing near-term revenues through the veterinary division, IsoPet, and through licensing. Our Medical Advisory Board has been expanded. Under the Chairmanship of Dr. Barry Pressman (a neuroradiology expert at Cedars-Sinai Medical Center in Los Angeles and Past-President of the American College of Radiology), the Board now includes Dr. Albert Denittis (Chief of Radiation Oncology Lankenau Medical Center), and Dr. Howard Sandlin (Ronald H. Bloom Chair in Cancer Therapeutics, Professor and Chair, Department of Radiation Oncology, Cedars-Sinai Medical Center). Their combined medical experience adds up to over 125 years. We have also been harvesting advice from other doctors, including two from the Mayo Clinic. The focus of the Advisory Boards is to prioritize our indications for use (which cancer types to treat first) in order to present them one at a time, in sequence to the FDA. The Board has selected 18 cancers that are good candidates for treatment with RadioGel™. To me, this large number is a confirmation of our belief that RadioGel has broad potential to treat a variety of tumors. From a business standpoint, it set the stage for incremental growth for many years into the future. In the near-term, we are prioritizing this list down to our top three therapy targets based on specific criteria. 1. Potential for FDA approval and successful therapy: a. Accessibility in the body, ease of application b. Therapeutic effectiveness in response to radiation c. Potential collateral risks from injection d. FDA Testing requirements 3. Business considerations a. Number of patients diagnosed yearly b. Ease of acceptance by the medical community c. Medical Insurance and Medicare reimbursement To paraphrase: 1) It works; 2) Nobody has a better mousetrap; and 3) It has to be profitable to the medical business sector. There have been other great products that made it through the FDA and failed, since the medical community did not see a profitable way to adapt the new technology. The medical community cares about saving lives, but they are in a business. We did not want to be surprised by that reality. As of today, we are down to six near-term candidates. We hope to have our final selection before the end of February. This is an important decision, so we need to get it right. I will send out another shareholder letter when we select our first indication for use. I will also discuss our veterinarian sector's business plan, as well as some updates in a near-term communication to you. I hope this was not too much detail, but I am not a big fan of fluff. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for cancer treatment. The IsoPet Solutions division is focused on utilizing RadioGel for a cancer therapy in animals. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales, and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners, and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


News Article | February 21, 2017
Site: www.prweb.com

The JBG Companies today announced the appointment of Steven Museles as Executive Vice President and General Counsel. In his new role, Mr. Museles will serve as a senior officer and member of the executive leadership team and as an advisor and resource to the Board of Trustees of JBG SMITH. Museles is an accomplished corporate attorney and brings extensive experience in strategic planning, corporate transactions, securities issuances, mergers and acquisitions and real estate investment trusts (REITs). Most recently, Mr. Museles was the Executive Vice President, General Counsel and Chief Compliance Officer with Alliance Partners LLC. Prior to that, Mr. Museles worked for 14 years with CapitalSource Inc. in many different roles including Executive Vice President and Chief Legal Officer, Co-Chief Executive Officer and member of the Board of Directors. Prior to CapitalSource, Mr. Museles was a partner at Hogan Lovells. Mr. Museles earned his JD from Georgetown University Law Center and BA from the University of Virginia. “We are thrilled to have Steve join our team,” said W. Matthew Kelly, Managing Partner of JBG and CEO designate of JBG SMITH. “With more than 25 years of experience working with public companies and REITs, Steve brings expertise and savvy that will be critical to our success as a public company for years to come.” JBG SMITH will be a newly created, publicly traded company listed on the New York Stock Exchange following the spin-off of Vornado’s Washington, D.C. business and its merger with certain select assets of the JBG Companies, expected to be completed in the second quarter of 2017. The addition of Mr. Museles to JBG SMITH rounds out the executive leadership team, following the appointment of Stephen W. Theriot as Chief Financial Officer announced on February 13, 2017. The new JBG SMITH Properties will be the largest and best-in-class, publicly traded, pure-play real estate company focused on the Washington, DC market. It will hold, directly or indirectly, (i) 72 operating assets aggregating approximately 21.4 million square feet, comprised of 52 office assets aggregating over 14.8 million square feet, 16 multifamily assets aggregating 6,432 units and four other assets aggregating approximately 785,000 square feet; (ii) four wholly owned office and multifamily assets under construction totaling approximately 821,000 square feet; (iii) nine near-term development office and multifamily assets totaling over 2.1 million estimated square feet; and (iv) 47 future development assets totaling approximately 23.5 million square feet of estimated potential development density.


News Article | February 28, 2017
Site: www.prnewswire.co.uk

- Opening panel debate featuring Volkswagen, Michigan Department of Transportation, American Center for Mobility, Panasonic Automotive and Cisco Jasper - New for 2017: second high-level panel discussion, featuring Covisint, Changan US R&D Center, Argus Cyber Security, Hogan Lovells and Booz Allen Hamilton - 20 speakers from OEMs, suppliers and other industry stakeholders Building on the success of the 2016 conference, Automotive Megatrends is delighted to return to Michigan with Connected Car Detroit. For 2017, the conference focus is on the rapidly developing opportunities enabled by the vehicle connectivity. Connected Car Detroit brings together the stakeholders responsible for the technology behind the connected car, and the services that connectivity facilitates. Great speakers, cutting-edge topics and fantastic networking opportunities with over 250+ automotive industry delegates will make it an unmissable conference. Connected Car Detroit will open this year with a keynote by Ola Cabs' Ankit Jain. Ankit heads up Ola Play, the connected car platform for ride-sharing launched recently by Indian online taxi aggregator, Ola Cabs. Speaking from the perspective of a multi-billion-dollar-valued mobility services operator, Ankit will highlight the challenges and opportunities of app-based ride-hailing in the Indian market and how that knowledge can be applied to any market. The morning panel discussion will look ahead to the connected car's longer-term prospects. 'Connected cars - the next ten years' will feature: For 2017, we've added a second panel discussion. This year's topic, 'Protecting the connected car', will be debated by: The one-day event will also include presentations from: For more information and to obtain tickets for this unique conference, please go to https://automotivemegatrends.com/connected-car-detroit/


DENVER--(BUSINESS WIRE)--Vention Medical (Vention), a KRG Capital Partners Fund IV (KRG) portfolio company and integrated services provider for the design, engineering and manufacturing of complex medical devices and components, has entered into merger agreements with separate buyers to sell the business in a two-step transaction. The Advanced Technologies segment will be acquired by Nordson Corporation, the leader in precision dispensing, fluid management, and related technologies and the Device Manufacturing Services segment will be acquired by MedPlast, Inc, a global services provider to the medical device industry. KRG expects the closing will occur in the second quarter of 2017. Stew Fisher, Managing Director at KRG, commented, “I would like to congratulate Dan Croteau and the entire Vention management team for their outstanding execution of the Company’s growth plan, establishing Vention as a technology and supply chain leader through organic growth and strategic acquisitions. During KRG’s ownership, Vention completed eight add-on acquisitions to further develop its global design and engineering services, proprietary component technology and supply chain capabilities. We wish the team all the best with their new partners, Nordson Corporation and MedPlast.” Vention’s President and Chief Executive Officer, Dan Croteau, added, “The partnership with KRG was integral in helping us drive unique customer solutions and accelerated growth through organic capital investment and add-on acquisitions. The sale of Vention marks a great outcome for our employees, customers and shareholders. Both Nordson Corporation and MedPlast have histories of acquiring great companies and making them even stronger. We thank KRG for their support and are excited about the prospects for both Vention businesses within Nordson Corporation and MedPlast.” KRG made its initial investment in Vention Medical in May of 2008, and this sale will represent the 10th full exit in KRG’s $1.96 billion fund IV. Piper Jaffray served as financial advisor and Hogan Lovells served as legal advisor to Vention on the transaction. About Vention Medical: Vention Medical is a global integrated solutions partner with more than 30 years of experience in design, engineering and manufacturing of complex medical devices and components. Vention Medical specializes in components and services used in interventional and minimally invasive surgical products including catheters, reinforced shafts, balloons, extrusions, polyimide tubing, heat shrink tubing, PTFE liner tubing, molded components, and finished device assembly and packaging. Visit Vention at ventionmedical.com. About KRG Capital Partners: Founded in 1996, KRG is a Denver based private equity buyout firm focused on “buy and build” investment opportunities in the lower middle market. KRG has approximately $4.4 billion of cumulative capital either deployed or available for future investment, which includes approximately $1.2 billion deployed since inception by institutional equity co-investors. The Firm seeks investment opportunities where KRG can work in concert with owners and operating managers who are committed to expanding their companies and becoming industry leaders. The result is a partnership that focuses on creating a significantly larger enterprise through a combination of internal growth and complementary add-on acquisitions. Visit KRG at www.krgcapital.com. About Nordson Corporation: Nordson Corporation engineers, manufactures and markets differentiated products used to dispense, apply and control adhesives, coatings, polymers, sealants, biomaterials, and other fluids; to test and inspect for quality; and to treat and cure surfaces. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in nearly 40 countries. For more information about Nordson Corporation, visit www.nordson.com. About MedPlast: MedPlast is a global services provider to the medical device industry. The company offers a range of engineering and manufacturing capabilities that support the world’s leading original equipment manufacturers with producing diagnostic, orthopedic, surgical and other medical products. Headquartered in Tempe, Ariz., the company operates 11 ISO-certified facilities around the world. For more information about MedPlast, visit medplastgroup.com.

Loading Hogan Lovells collaborators
Loading Hogan Lovells collaborators